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Abstract
Adjuvant chemotherapy for non-small-cell lung carcinoma (NSCLC) is a debated issue in clinical oncology.
Although it is considered a standard for resected stage II-IIIA patients according to the available guidelines, many
questions are still open. Among them, it should be acknowledged that the treatment for stage IB disease has
shown so far a limited (if sizable) efficacy, the role of modern radiotherapies requires to be evaluated in large
prospective randomized trials and the relative impact of age and comorbidities should be weighted to assess the
reliability of the trials’ evidences in the context of the everyday-practice. In addition, a conclusive evidence of the
best partner for cisplatin is currently awaited as well as a deeper investigation of the fading effect of
chemotherapy over time. The limited survival benefit since first studies were published and the lack of reliable
prognostic and predictive factors beyond pathological stage, strongly call for the identification of bio-molecular
markers and classifiers to identify which patients should be treated and which drugs should be used. Given the
disappointing results of targeted therapy in this setting have obscured the initial promising perspectives, a
biomarker-selection approach may represent the basis of future trials exploring adjuvant treatment for resected
NSCLC.
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Background
Adjuvant chemotherapy (ACT) for NSCLC still repre-
sents a major topic in clinical oncology. According to
guidelines from the European Society of Medical Oncol-
ogy (ESMO) [1], American Society of Clinical Oncology
(ASCO) [2], National Comprehensive Cancer Network
(NCCN) [3] and American College of Chest Physicians
(ACCP) [4,5] cisplatinum based ACT is now considered
a standard treatment for resected stage II-IIIA with an
estimated survival benefit of 4-5% at 5 years. Neverthe-
less, many issues such as the management of stage IB,
the role of postoperative radiotherapy (PORT), the treat-
ment of elderly-unfit patients, the best regimen and
schedule to be used and the long term effects of ACT,
are still under investigation. Moreover, the narrow ACT
therapeutic index (i.e. limited survival benefit with con-
siderable toxicity) requires a careful assessment of
expected risks and benefits for each patient.
To date, no other prognostic or predictive factors
beyond pathological stage have been prospectively vali-
dated. Molecular markers or classifiers could better
identify which patients should be treated with, or spared
by, chemotherapy and which drugs should be better
used (assuming a differential sensitivity to a particular
agent/regimen). Despite researchers’ efforts, this still
represents an unmet medical need. The purpose of this
review is to summarize the available evidences on ACT
in the context of the new recent advances in the field of
translational and bio-molecular research.
The historical perspective: so far, so good?
Since the NSCLC Collaborative Group landmark meta-
analysis, which first indicated a small benefit in favor of
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trials have been released with conflicting results.
The Adjuvant Navelbine International trial association
(ANITA) trial [7] and the National Cancer Institute of
Canada Clinical Trial Group (NCIC CTG) JBR-10 trial
[8] confirmed the OS benefit of Cisplatinum and Vinor-
elbine adjuvant chemotherapy. The former enrolled
stage I-IIIA patients and allowed the use of PORT,
while the latter was limited to IB-II without radiother-
apy. The OS improvement was 8.6% and 15% at 5 years,
with HR of 0.79 and 0.7 respectively, maintained at
longer follow up [7,9]. The International adjuvant lung
cancer trial (IALT) [10], despite positive results at first
analysis (4% reduction in the risk of death in enrolled
stage II-IIIA patients undergoing platinum based ACT
with either etoposide or vinca alkaloids [11]), failed to
maintain the same benefit with longer follow up. So did
the “stage IB-focused” CALBG 9633, which used a car-
boplatinum based regimen [12,13]. The negative results
of the Big Lung Trial (BLT) [14], the Adjuvant Lung
Project Italy (ALPI) [15] and ECOG 3590 [16] further
jeopardized evidence on ACT.
The description of each trial is beyond our aim, how-
ever differences in study design, patient selection, sche-
dule/regimen administered, and use of PORT could
partially explain the conflicting outcomes [17].
In 2008 the LACE meta-analysis pooled individual
patients’ data from 5 of these trials [7,8,10,14,15] (using
modern platinum based -ACT and conducted after
1995; 4584 patients) and showed a statistically signifi-
cant absolute OS benefit of 5.4% (HR for death = 0.89;
95% CI 0.82-0.96; p = .005) [18].
The results of other meta-analysis [19-22] showed
similar HR/RR for death for platinum based -ACT (0.86
-0.93), regardless of the method used (individual
patients’ data vs abstracted data). So did the recent
update of the NSCLC-meta-analysis Collaborative
Group (HR 0.89. 95% CI 0.82-0.97, p = 0.006 HR 0.86.
95% CI 0.81-0.92, p < .0001, absolute OS benefit: 4% at
5 years for the overall population)[23]. In a larger set-
ting, community based surveys or multinstitutional data-
base analyses show an increasing employment of ACT
(with a consequent survival improvement) [24-29].
These data, interpreted with the caution requested by
their retrospective and not randomized fashion, suggest
that the benefit may also be extended into the context
of patients treated in routine clinical practice.
With the aim to better interpret the quantitative and
qualitative differences among randomized clinical trials
results, IALT, JBR-10 and ANITA were analyzed with a
bayesian approach, weighting the results on the basis of
continuously updated outcome hypotheses [30]. Never-
theless, the 13% relative death risk reduction corre-
sponding to an absolute 4-5% survival benefit did not
increase overtime when considering the former NSCLC
Collaborative Group meta-analysis publication [6] and
its recent update [23]. These small benefit strongly call
for an optimization of the therapeutic index of adjuvant
treatment.
The stage IB dilemma: Does (just) the size
matters?
The management of stage IB (according to the 6th
TNM edition) is still controversial. To date, evidence
s h o wt h a tb e n e f i tf r o ma d j u v a n tc h e m o t h e r a p yf o r
stage IB, if any, is small: 43 IB patients should be trea-
ted for one to benefit (number needed to treat, NNT),
nearly 3 times the 15 NNT for stage II-IIA [2]. In
addition, available results come from a trial with lim-
ited sample size (CALGB 9633) and from subgroup
analysis of other randomizedt r i a l s( w i t hf e we n r o l l e d
stage IB patients), both underpowered to detect the
small differences expected in OS.
In this regard, both the CALBG 9633, specifically
designed for stage IB disease, and subgroup analyses of
the IALT, JBR-10 and ANITA [7,8,11] trials failed to
demonstrate any survival benefit [13]. A possible benefi-
cial effect was seen for tumors larger than 4 cm (in
comparison with smaller tumors) in CALBG 9633 (HR
0.69; p = .043 vs HR = 1.12; p = .32) [13] and JBR-10
(HR 0.66 vs 1.73) [8]. Since both these analyses were
post-hoc, results are not conclusive, given also that the
benefit lowers overtime [31]. Similarly, in LACE meta-
analysis stage IB only trended toward an OS benefit.
The HR was 0.93 (95% CI 0.78-1.10), against 0.83 and
1.14 for stage II-III and IA, respectively [18].
The subgroup analysis from the NSCLC CG meta-
analysis update according to stage [23] and limited
to platinum-based regimens, showed an identical 5
years OS improvement of 5% for stage IB (from 55
to 60%), stage II (from 40 to 45%) and stage III
(from 30 to 35%), with a non significant test for
trend (p = 0.13) [23].
A 11% 5 years survival gain (from 74% to 85%) was
observed in Japanese patients with resected stage Ib ade-
nocarcinoma treated for 2 years with oral Uracil-Tega-
fur. Although promising, these results cannot be directly
extendend to Western countries whereas Uracil-Tegafur
has not been reliably tested so far [32].
Conducting prospective trials restricted (and pow-
ered) for stage IB patients would be the only way to
unravel this issue. However, the prohibitively large
sample size required undermines the feasibility of such
an approach [33].
In addition, other (molecular) prognostic factors are
needed to identify among these borderline patients,
those at higher risk. Nonetheless, the worse prognosis
observed with increasing T size has been recognized in
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and T2b (5 -7 cm), with a OS of 58 and 49% at 5 years,
respectively (p < .0001) [34]; T2bN0 was upstaged to
stage IIA [35]. Correlation with the new staging system
failed to validate the 5 cm cut-off in the 9-years update
of CALGB 9633, showing a trend towards a significant
benefit for adjuvant treatment for patients with tumors
> 7 cm [HR = 0.53; p = .051] [31], although interaction
should be investigated.
Recent studies investigated further pathological prog-
nostic factors for resected VII edition-stage IB (T2aN0),
such as the presence of microscopic vascular invasion
[36] or intratumoral vascular and/or visceral pleural
invasion [37]. Although promising, these results require
a prospective external validation.
Finally, the question of ‘which stage IB deserves adju-
vant treatment’ remains still unanswered. Size may
represent a selection criterion, while awaiting for more
powerful pathological and biological predictors.
Post Operative Radiotherapy (PORT): has the
1998 sentence expired?
Few and underpowered randomized clinical trials
exploring the role of PORT in patients after resection
of NSCLC have been conducted from the early 90s,
with inconclusive results. In order to look for a small
survival benefit, the individual patients’ data PORT
meta-analysis (initially including 9 randomized clinical
trials) was performed [38]. The last update (11 trials,
2343 patients) showed a statistically significant detri-
mental effect on OS for patients receiving PORT (HR =
1.18; 95% CI 1.07-1.31; p = .0001; 5% 2-years absolute
difference). Similar conclusions were reached for local
and distant Recurrence-Free Survival (RFS) (HR = 1.12,
p=. 0 3a n dH R=1 . 1 3 ,p=. 0 2 ,r e s p e c t i v e l y ) .Ah i g h l y
significant interaction according to stage and nodal sta-
tus was detected, indicating a substantial absence of
PORT effect in stage III or N2 patients (HR 0.99 and
0.97), restricting the detrimental difference to lower
stage disease [39].
Abandoned techniques, such as Cobalt-60, large irra-
diation fields (including the entire mediastinum), differ-
ent total doses (30-60 Gy), unconventional daily
fractions (up to 2,6-3 Gy) represent some of the limita-
tions of the trials included in the PORT meta-analysis,
thus undermining its validity in a modern setting. One
of the hypotheses is that the excess in non cancer
related deaths, mainly due to cardiovascular and lung
toxicity, could have outweighed the potential small ben-
efit on local recurrence [40].
The effect of PORT was also assessed in an unplanned
analysis of the ANITA trial. Although no formal statisti-
cal comparison could be made between subgroups, a
positive effect of PORT was suggested for N1 patients
in the control arm and for N2 patients overall [41]. The
latter derived the largest benefit from the association of
adjuvant chemotherapy plus PORT, followed by che-
motherapy alone, PORT alone and observation (5-years
OS: 47.4%, 34%, 21.3%, 16.6%, respectively) [7].
Although retrospectively derived on a relatively small
sample size, these results provide intriguing data on the
effect of modern PORT after optimal adjuvant
chemotherapy.
Data from more recent series (although retrospective
or community-based) showed a decreasing treatment
related death rate with modern techniques such as 3-
dimensional (3D) or imaging guided (IMRT) to mini-
mize irradiation of normal tissues (heart and lungs) and
maximize the optimal delivery to the targeted fields
[42]. A better selection of patients (i.e. only those with
extended mediastinal involvement [43] or at higher risk
of relapse [44]) may potentially increase the PORT ther-
apeutic index.
Although large, well-designed, prospectively trials eval-
uating the efficacy of modern PORT are required, the
CALGB 9734 prematurely closed due to slow accrual.
The Lung Adjuvant Radiotherapy Trial (Lung ART-
NCT00410383) comparing 3D-conformal PORT with no
PORT in resected N2 patients after the delivery of any
planned (neo)-adjuvant chemotherapy is currently
ongoing.
Treatment efficacy according to age
Older age and comorbidities may profoundly affect
treatment tolerability and overall mortality rate. Few
trials have been specifically conducted in elderly (and
frail) patients; thus, the vast majority of data derive from
retrospective analyses of randomized clinical trials
designed for an adult population.
In the subgroup analysis from the JBR-10, no differen-
tial effect favoring adjuvant chemotherapy according to
age (cut-off 65-years) was found; indeed, in the 155
patients over 65-s, the HR for death still favored adju-
vant treatment (0.61; 95% CI 0.38-0.98; p = .04), in spite
of the smaller cumulative doses of cisplatin and vinorel-
bine [45].
The update of the LCCG meta-analysis did not show
differential effect of adjuvant chemotherapy according to
age [23], as well as the LACE pooled analysis. In addi-
tion, no difference in severe toxicity were encountered
according to age (lower cumulative doses?)[46].
A recently published practice-based survey from SEER
registry showed that platinum based ACT administered
outside of clinical trials to unselected elderly patients
was associated with a significant survival benefit
(although limited to those under 80-years and associated
with a higher risk of serious adverse events)[28]. More-
over, the data from the Cancer Ontario Registry
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populations (even if any apparent increased toxicity was
observed)[26].
The LCCG meta-analysis did show a significant trend
(p = 0.002) against the adoption of adjuvant chemother-
apy in patients with a worsening performance status
(PS) [23] In this regard, LACE subgroup analysis showed
increasing benefits from adjuvant chemotherapy with
better PS (0 vs 1), with a detrimental effect for PS 2
(test for trend p = .009 for OS) [18].
These results suggest no differential effect of adjuvant
chemotherapy when age is the only variable [47], at
least when interpreting data from the available rando-
mized clinical trials; whether the daily elderly patient
might derive the same benefit from adjuvant chemother-
apy should be weighted in the context of comorbidities
and other prognostic factors.
Cisplatinum-based chemotherapy: is there a
‘winning’ doublet?
Clear and definitive evidence with regard to which
would be the best partner to be associated with adjuvant
cisplatinum is still awaited. The current opinion, gener-
ally shared by ASCO, NCCN, ACCP, and ESMO, is that
any cisplatinum-combination (according to the approved
dose and schedules for advanced setting) may be admi-
nistered to patients who have undergone radical resec-
tion and who are (at least apparently) disease-free after
surgery [1-5]. In addition, doses and schedules should
be tailored according to the patients’ compliance and
the physicians’ attitude ("practitioners adopt one cispla-
tin-based chemotherapy regimen to use consistently to
ensure familiarity and optimize patient safety”) [2]. This
‘opened-minded’ instead of ‘rigorous’ interpretation of
available scientific evidence represents a matter of dis-
cussion, although it should be recognized that clear
recommendations with modern regimens for the daily
practice are lacking and are still far to be produced.
With regard to the available evidences to date, the
combination cisplatinum plus vinorelbine should be
considered to have a ‘groundless supremacy’. Indeed, in
the prospectively planned subgroup analysis from
LACE, cisplatinum and vinorelbine trended toward a
major benefit (HR = 0.80; 95% CI. = 0.7-0.91; p < .001)
if compared to other regimens (interaction test p =
.004) [18], and this benefit was stage dependent (inter-
action p = .02).
Currently, two issues should be considered: a) patients
receiving > 300 mg/m2 of cisplatinum performed better
than those receiving < 300 mg/m2. This featured patient
subgroup overlaps for almost 65% with that of patients
receiving vinorelbine, in comparison with half of those
receiving other regimens. Whether the benefit of cispla-
tinum and vinorelbine depends on the combination of
the 2 drugs or from higher cisplatinum dose cannot be
easy established [18]; b) the planned schedule of cisplati-
num was 50 mg/m2 day 1 and 8 in JBR10 and 100 mg/
m2 day 1 in ANITA; vinorelbine in both trials was
meant to be delivered 25-30 mg/m2 weekly for 4 cycles
(16 doses). In JBR10 the actual dose was 84% and 52%
for cisplatinum and vinorelbine respectively, with higher
toxicities occurring in older, female and after pneumo-
nectomy [48]. In ANITA only 50% of patients com-
pleted the planned 4 cycles.
The ‘fading effect’ of chemotherapy
According to the breast or colon cancer models, the
benefit of adjuvant treatmen tm a yv a r yo v e rt i m e ;t h e
data from NSCLC are conflicting. Long term effect of
platinum based ACT was maintained in ANITA after 5
years and in the 7-years (projected) analysis (OS benefit
of 8.6% and 8.4%, respectively)[7] and in JBR10 (absolute
OS benefit of 11%, after 9.3 years and 12% at 5 years)[9].
However the updated results of CALBG 9633 [13] and
IALT [11] did rise many concerns.
CALBG 9633 first analysis (at 2.8 years) showed a pro-
mising 11% OS increase in stage IB, which lead to early
stopping of the study [12]. Unfortunately this was no
longer confirmed after the 4.5 [49] and 6 years updates
[13]. In the IALT trial (the largest with 1867 patients), the
OS benefit after the 90 months analysis was less evident
(and not statistically significant anymore) in comparison
with the analysis performed at 56 months (HR 0.91 and
0.56, respectively). The rate of non-lung cancer related
deaths increased by 20%, as compared with the first
interim analysis, mostly after 5 years of follow up [11].
Although the unbalanced population taken into account
after the 5-years time-point should to be considered as a
randomized comparison, long term side effects of citotoxic
drugs and the high rate of comorbidities in NSCLC
patients may partially explain these results [50]. However
some differences in classification and reporting of death
causes may have influenced the reported outcomes [17].
LACE data show a sustained effect of ACT over time
(survival gain of 3,9% and 5,4% at 3 and 5 years, respec-
tively). Considering only lung cancer-related deaths, the
benefit was even higher (+ 6,9% at 5 years), partially
outweighed by the higher rate of non lung cancer-
related deaths observed in the ACT group.
The integration of bio-molecular predictors in the
risk assessment process: are they ready for prime
time?
An effective risk assessment is essential to identify
“high-risk” stage IB (IA?) patients benefiting from ACT
and spare some “low-risk” stage II from the toxicities of
a treatment not impacting on their OS. Which factors
should be considered in this clinical decision process?
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Pathological stage is the only prospectively validated
prognostic factor to guide the prescription of adjuvant
chemotherapy, although based on inadequate prognostic
power to stratify patients within the same TNM cate-
gory [51,52]. Older age, male gender, poorer PS and
non-squamous cell histology are currently known to be
associated with decreased survival, although their addi-
tional weight to clinical staging does not increase its
prognostic power [53].
We previously investigated the independent prognostic
role of the number of resected nodes and of the ratio
between metastatic and resected nodes. The generated
prognostic model was able to powerfully stratify patients
into 3 classes [54]. Recently, a large retrospective analy-
sis from the SEER database showed that the increasing
number of resected positive nodes and a higher ratio
between metastatic and overall resected nodes have an
independent negative prognostic impact for overall sur-
vival in N1 patients [55,56]. Although a prospective vali-
dation is mandatory, these results suggest the inclusion
in the next TNM of other nodal descriptors than site
and status to improve the prognostic power.
Molecular factors
Several molecular prognostic (and predictive) models have
been published in the attempt to improve the clinical deci-
sion process [57-62]. Although promising, their effective-
ness and clinical utility were undermined by several
limitations: the inability to account for comorbidities and
other clinical factors (which affect prognosis) [63], metho-
dological and statistical biases, lack of a solid and reprodu-
cible internal and external validation [64,65].
The proposal of a new prognostic model should always
be supported by reliable validations. A pivotal example is
represented by the recent retraction by Potti et al of their
promising metagene expression model (which led to stop
the CALBG 30506 trial and to remove the metagene ana-
lysis from the study design) [66].
The analysis of the data from the available randomized
trials exploring the role of eventual predictors for either
prognosis or treatment efficacy hides many drawbacks
given its retrospective nature. This is further compli-
cated by the extremely relevant impact of the attrition
rate for the analysis of biological samples [67]. Never-
theless, many investigators involved in those trials
exploring the benefit of adjuvant chemotherapy planned
and conducted intriguing analyses to generate working
hypotheses for future biomarker-driven randomized
trials, as follows:
￿ IALT-BIO: the low IHC expression of the excision
repair cross complementation group 1 (ERCC1)
represents a marker of better outcome in patients
receiving cisplatinum in ACT (HR = 0.65; p = .0002
vs HR = 1.14; p = .4 for high expression; interaction
test p = .0009); conversely, high ERCC1 expression
correlates with longer OS in the control group (HR
= 0.66) [68]. In the context of cell cycle regulators,
p27, while having a predictive role for patients trea-
ted with ACT, does not affect prognosis (p27 nega-
tive HR 0.66; p = .006; p27 positive HR 1.09; p =
.54; interaction test p = .02)[69]. Similarly to ERCC1,
the low expression of MutS homologue 2 (MSH2)
was predictive of benefit from platinum based -ACT
(low MSH2 HR = 0.76; p = .03 vs high MSH 2 HR
= 1.12; p = .48; interaction test p = .06). MSH2 high
expression was also prognostic for longer survival in
untreated patients (HR = 0.66; p = .01)[70]. In order
to test the prognostic power of the combination of
these 3 markers, patients were clustered into 4 cate-
gories according to low/high level of MSH2/ERCC1:
the benefit from ACT decreased with the increasing
number of positive markers (HR for low ERCC/low
MSH 20.65; p = .01). Similar results were shown for
p27/ERCC1. Nevertheless, the prognostic effect
decreased over time [70]. The other analyzed mar-
kers had a weaker or null predictive role [71,72].
￿ JBR-10-[BIO]: K-RAS wt and p-53 wt patients
seemed to benefit more from ACT with cisplatinum
and vinorelbine (vs mutants) although the interac-
tion test for treatment effect was not significant. P53
expression was prognostic of worse OS in the con-
trol arm (HR = 1.89; p = .03), while in the treatment
arm it had a positive predictive role (HR = 0.54; p =
.02)[73]. From JBR-10 dataset an m-RNA based-15
gene signature was proposed to differentiate high
from low risk patients. The HR for death in the
observation group was 18 (adjusted at multivariate
analysis; 95% CI 5.12-44.04; p < .001). The prognos-
tic power was validated on 4 separate dataset and by
RT-PCR on the original dataset. The positive predic-
tive role was confirmed for high risk group (HR of
death 0.33; 95% CI 0.17-0.63; p = .0005) but not for
low risk (HR = 3.67; p = .21). The external, prospec-
tive validation is awaited to confirm these results
[74]. Although unpowered to assess the prognostic
or predictive impact of EGFR mutation and copy
number, a possible trend toward a positive predictive
role of the mutation (and copy number) was pro-
posed in JBR10.
￿ LACE BIO (ANITA, JBR10, IALT and CALBG
9633): High class III beta tubulin (TUBB3) expres-
sion maintained the negative prognostic impact seen
in previous analysis (HR for death = 1.3; p = .001).
In metastatic setting, high TUBB3 expression caused
resistance to tubulin-targeting agents [75]. No effect
in adjuvant setting was detected (interaction test p =
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high expression [76]. Other analyses were performed
to assess the prognostic and predictive value of p-53
and KRAS. While neither P53 IHC expression nor
mutation were prognostic for survival, a trend
t o w a r dap o s i t i v ep r e d i c t i v er o l ew a ss e e ni nw i l d
type patients (significant for squamous cell) [77].
Regarding KRAS, a non significant trend toward a
worse OS was seen for mutated patients (significant
only for non squamous non adenocarcinoma), with
predictive role [78].
￿ Other studies: additional potential biomarkers or
classifiers involving different pathways (DNA
methylation, mTOR, cytoskeleton protein expres-
sion) have been retrospectively evaluated in other
studies. Results are promising but should be vali-
dated in prospective larger randomized clinical
trials [79-82].
The target therapy paradox
The biomarker-selection approach, i.e. the treatment
assignment according to the expression of featured
molecular/classifier signatures (for example ERCC1 and
BRCA1 for cisplatinum, RRM for gemcitabine) is the
basis of many ongoing clinical trials in order to further
optimize and customize ACT (table 1).
While target therapy has dramatically changed the
treatment of advanced stage NSCLC, its results in
resected NSCLC are currently disappointing. Indeed, the
JBR-19 trial, designed to evaluate the benefit of Gefitinib
regardless of chemotherapy in unselected patients with
resected stage IB-IIIA, did not show any benefit over
placebo (and prematurely closed on the basis of the
negative results of the ISEL [83] and SWOG 0023 trials
[84]) [85]. Moreover, although underpowered to draw
definitive conclusions (500 patients out of the 1200
planned), even in the EGFR-mutant patient subgroup no
difference in favor of Gefitinib was determined. In this
trial, both EGFR mutation/amplification and K-RAS sta-
tus were neither prognostic for OS nor predictive of
outcome.
These disappointing data suggest that: 1) the efficacy
of the administration of a targeted agents in patients
expressing a sensitizing biomarker, may be diluted in
the context of an unselected population; 2) the biologi-
cal background behind advanced and surgically
removed disease can be extremely different. In this
direction, retrospective analyses, such as the one from
the MSKCC, indicate a potential benefit (a trend
toward better disease-free survival) of Gefitinib or
Erlotinib after adjuvant chemotherapy in EGFR-mutant
patients [86]. The results of the ongoing RADIANT
trial, randomizing only EGFR positive patients (IHC or
Table 1 Ongoing clinical trials in adjuvant setting
Trial/
Acronym
Stage Marker Design Notes
RADIANT I-IIIA EGFR IHC pos 4 cycles of optional ACT followed by 2 years of
TKI or placebo
￿ Phase III, placebo controlled; Erlotinib 150 mg/die
× 2 years
￿ Primary endpoint: DFS
ECOG 1505 IB (> 4 cm)-
IIIA
None Clinician choice ACT vs Clinician choice ACT +
Bevacizumab
￿ Phase III (2:1); Bevacizumab 15 mg/kg/3 wks
￿ Primary endpoint: OS
￿ Secondary endpoint: DFS, toxicities
SCAT I-IIIA BRCA CDDP DOC vs “gen assigned CT”￿ Phase III (3:1) CDDP DOC/DOC/CDDP GEM vs
CDDP/DOC
￿ Primary endpoint: DFS
￿ Secondary endpoint: OS, toxicities
TASTE I-IIIA ERCC1/EGFR
mutant
CDDP/ERL ￿ Phase II feasibility
SWOG 0720 I ERCC1/RRM1 Follow up or ACT according to risk profile ￿ Phase II feasibility
MAGRIT IB-IIIA MAGE A3 + Vaccine vs placebo after optional ACT ￿ Phase III (2:1) placebo controlled; separate
analysis for ACT +/-
￿ Primary endpoint: DFS
￿ Secondary endpoint: OS
ITACA II-IIIA ERCC1/TS ACT assigned according to markers expression ￿ Phase III
￿ Primary end-point: OS
TREAT IB-IIIA None CDDP PEM vs CDDP GEM ￿ Randomized phase II
￿ Primary endpoint: feasibility
￿ Secondary endpoint: toxicity, delivery
EGFR: epidermal growth factor receptor; IHC: immunohistochemistry; ACT: adjuvant chemotherapy; TKI: tyrosine kinase inhibitors; DFS: disease-free survival; OS:
overall survival; CDDP: cisplatin; DOC: docetaxel; GEM: gemcitabine; ERCC: Excision Repair Cross-Complementation gene; RRM: ribonucleotide reductase M1 gene;
MAGE: melanoma-associated antigen; TS: thymidylate synthetase; PEM: pemetrexed.
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ACT, are awaited.
Conclusions
ACT for radically resected NSCLC is now part of the
routine clinical approach to early NSCLC and is cer-
tainly contributing to the decrease in mortality observed
in these patients in recent years. While many important
‘technical’ questions, such as optimal treatment for
Stage I patients, best platinum based combination, and
optimal use of PORT to name a few, remain to be
answered to further refine currently achievable results,
the biggest challenge ahead is to better understand the
underlying biology of the disease and to incorporate bio-
logical advances into clinical treatment algorithms.
Ongoing adjuvant trials, such as the italian ITACA, will
hopefully assess the role of pharmacogenomically ‘tai-
lored’ ACT to optimize the use of currently available
classical cytotoxic agents; however, genetic and epige-
netic drivers of early NSCLC must be clearly identified
in order to generate a further ‘leap’ in the management
of resectable NSCLC patients, both in terms of accurate
prognostication and risk assessment and in terms of bet-
ter prediction of sensitivity/resistance to specific tar-
geted treatments. The ever growing knowledge on
molecular pathways, cancer stem cell populations, and
genetic/epigenetic programs regulating the invasive and
metastatic phenotype will shed new light on the right
path to be undertaken in order to ensure the best treat-
ment to each specific patient population.
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